Celcuity Inc. Share Price

Celcuity Inc. Share Price

NASDAQ: CELC | Mid Cap
$69.17
-$0.26 (-0.37%) Last updated on 30 Oct, 2026 | 00:00 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Celcuity Inc. Stock Performance

Open
$71.66
Prev. Close
$69.43
Circuit Range
N/A
Day Range
$69.09 - $72.95
Year Range
$53.67 - $151.01
Volume
24,233
Average Traded
$70.91

Celcuity Inc. Share Price Today

As of 30 October 2026, Celcuity Inc.'s share price is $69.17. The stock opened at $71.66, compared to its previous close of $69.43. During today's trading session, Celcuity Inc.'s share price traded between $69.09 and $72.95, with an average price of $71.02. Over the past 52 weeks, the stock has recorded a high of $151.01 and a low of $53.67. In terms of performance, Celcuity Inc.'s share price has declined by 43.00% over the last six months and is down 10.34% on a year-on-year basis.

Celcuity Inc. Share Price Chart

Line chart of the Celcuity Inc. price trend over the selected period. The price fell overall, ranging from 69.09 to 73.05, ending at 69.17.
$69.09$72.95
L
Show Current Price
H

Celcuity Inc. Stock Fundamentals & Key Indicators

Market Cap
$3.23B
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-4.63
Revenue (TTM)
$0.00
Return On Equity (TTM)
1772.02%
Profit Margin
N/A
Debt to Equity
-58.93
Quarterly Earnings Growth YoY
-80.05%

Celcuity Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$43.80-$50.97-$52.84-$78.86
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-16.37%-3.67%-49.24%

Celcuity Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$40.37-$63.78-$111.78-$177.04
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-57.99%-75.26%-58.38%

About Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Celcuity Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$78.93
$69.09
-13.23%
Sep 2026
$90.94
$79.62
-14.67%
Aug 2026
$84.91
$93.31
+7.89%
Jul 2026
$105.78
$86.48
-17.41%
Jun 2026
$130.32
$104.71
-21.04%
May 2026
$120.75
$132.61
+9.27%
Apr 2026
$117.56
$121.36
+6.40%
Mar 2026
$110.89
$114.06
+2.08%
Feb 2026
$111.14
$111.74
+2.13%
Jan 2026
$99.71
$109.41
+9.80%
Dec 2025
$100.25
$99.64
-1.51%
Nov 2025
$77.72
$101.17
+31.13%

CELC Share Price FAQs